Talphera, Inc.
NASDAQ: TLPH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Vincent J. Angotti
- Employees
- 13
- Headquarters
- San Mateo, United States
- IPO year
- 2011
- Market cap
- $21.7M
- Website
- https://talphera.com
Loading TLPH…
Loading profile data…Frequently asked questions about TLPH
What does Talphera, Inc. (TLPH) do?
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigation...
Where does TLPH trade?
Talphera, Inc. (TLPH) trades on the NASDAQ Global Market.
What sector is TLPH in?
Talphera, Inc. (TLPH) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Talphera, Inc.?
Vincent J. Angotti is the chief executive officer of Talphera, Inc. (TLPH).
Where is Talphera, Inc. headquartered?
Talphera, Inc. is headquartered in United States.
Does TLPH pay a dividend?
Talphera, Inc. (TLPH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TLPH go public?
Talphera, Inc. (TLPH) completed its initial public offering in 2011.